APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/811,725	03/29/2004	Sateesh Apte	14705	1415
28061 7 THEODORE J. 1	590 01/10/2007 BIELEN JR.	EXAMINER		
1390 WILLOW PASS ROAD SUITE 1020 CONCORD, CA 94520			PARKIN, JEFFREY S	
			ART UNIT	PAPER NUMBER
,			1648	
·				
SHORTENED STATUTORY	PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE	
31 DAYS		01/10/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

		Application No.	Applicant(s)				
Office Action Summary		10/811,725	APTE, SATEESH				
		Examiner	Art Unit				
		Jeffrey S. Parkin, Ph.D.	1648	•			
Period fo	The MAILING DATE of this communication Reply	on appears on the cover sheet w	ith the correspondence addres	§S			
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR CHEVER IS LONGER, FROM THE MAILInsions of time may be available under the provisions of 37 SIX (6) MONTHS from the mailing date of this communical openiod for reply is specified above, the maximum statutor to reply within the set or extended period for reply will, be reply received by the Office later than three months after the patent term adjustment. See 37 CFR 1.704(b).	ING DATE OF THIS COMMUNI CFR 1.136(a). In no event, however, may a ttion. y period will apply and will expire SIX (6) MOI by statute, cause the application to become A	CATION. reply be timely filed NTHS from the mailing date of this commu BANDONED (35 U.S.C. § 133).	·			
Status							
1)[Responsive to communication(s) filed or	n 29 March 2004	•				
2a)□	_ ` _	☐ This action is non-final.	•				
3)□	-						
٠,٣	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposit	ion of Claims	•	,				
· _	Claim(s) <u>1-6</u> is/are pending in the application	ation					
•	4a) Of the above claim(s) is/are w						
	Claim(s) is/are allowed.	illiarawii iroin consideration.					
	Claim(s) is/are rejected.	•		i			
-	Claim(s) is/are objected to.			•			
·	Claim(s) <u>1-6</u> are subject to restriction an	d/or election requirement.		•			
Applicat	ion Papers			·			
· · · _	•	rominar					
	The specification is objected to by the Ex The drawing(s) filed on is/are: a)[<u></u>	by the Evaminer				
الران	Applicant may not request that any objection	, , ,	•	•			
	Replacement drawing sheet(s) including the			121(d)			
11)	The oath or declaration is objected to by						
	under 35 U.S.C. § 119						
	•	iii	0.440(-) (4) (0)				
	Acknowledgment is made of a claim for f ☐ All b)☐ Some * c)☐ None of:	oreign priority under 35 U.S.C.	3 119(a)-(a) or (t).				
a)	1.☐ Certified copies of the priority doc	umante have been received					
	Certified copies of the priority documents of the priority docume		Application No				
	3. Copies of the certified copies of the		· · ·	ae			
•	application from the International I	•	, rooorroa in tino rrational ota,	90			
* 5	See the attached detailed Office action for	` ''	received.				
		·	•				
•			•				
• • •							
Attachmen	• •	n □ 1-1-1	O.,				
	ce of References Cited (PTO-892) the of Draftsperson's Patent Drawing Review (PTO-9		Summary (PTO-413) (s)/Mail Date				
3) Infon	mation Disclosure Statement(s) (PTO/SB/08)	5) Notice of	Informal Patent Application				
Pape	r No(s)/Mail Date	6) 📙 Other:	_ ·				

Serial No.: 10/811,725 Docket No.: 14705
Applicant: Apte, S. Filing Date: 03/29/2004

Restriction Requirement

35 U.S.C. § 121

Restriction to one of the following inventions is required under 35 U.S.C. § 121:

- a. Group I, claim(s) 1-3, drawn to a therapeutic suspension comprising HIV-1 nef-deficient viral particles, classified in class 435, subclass 236.
- b. Group II, claim(s) 4 and 6, drawn to a method for reducing the HIV-1 viral load, classified in class 424, subclass 208.1.
- c. Group III, claim(s) 5, drawn to a method for restoring cytotoxic T lymphocyte activation pathways, classified in class 424, subclass 208.1.

The inventions are distinct, each from the other because of the following reasons:

Product and Process of Using

Inventions I and II/III are related as product and processes of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (M.P.E.P. § 806.05(h)). In the instant case, the product of Group I can be employed in a number of materially different processes such as the generation of immunological reagents or in therapeutic methods to reduce the viral load.

Unrelated Inventions

Inventions II and III are unrelated. Inventions are unrelated

if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (M.P.E.P. § 806.04 and § 808.01). In the instant case, each of the identified groups is directed toward a different scientific objective and will ultimately employ different reagents and protocols. Separate searches will also be required for each group. Therefore, each invention is clearly directed toward a different inventive concept.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, recognized divergent subject matter, and require separate searches, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 C.F.R. § 1.143). Applicant is also advised that the claims should be amended to reflect the election, where necessary.

Claim Rejoinder (M.P.E.P. § 821.04)

Applicants are reminded that a restriction between product and process claims has been set forth *supra*. When applicant elects claims directed to the product, and a product claim is subsequently found to be allowable, withdrawn process claims that depend from or otherwise include **all** the limitations of the allowable product claim will be rejoined in accordance with the provisions of § 821.04 of the M.P.E.P. Process claims that depend from or otherwise include **all** the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier.

Serial No.: 10/811,725 Applicant: Apte, S.

Amendments submitted after final rejection are governed by 37 C.F.R. § 1.116 while amendments submitted after allowance are governed by 37 C.F.R. § 1.312.

In the event of rejoinder, the requirement for restriction. between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 C.F.R. § 1.104. be allowable, the rejoined claims must meet all criteria for patentability as set forth under 35 U.S.C. §s 101, 102, 103, and Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See AGuidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer, and 35 U.S.C. § 103(b), 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product Failure to do so will result in a loss of the right to rejoinder. Furthermore, note that the prohibition against double patenting rejections of 35 U.S.C. § 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See M.P.E.P. § 804.01.

Correspondence

Any inquiry concerning this communication should be directed to Jeffrey S. Parkin, Ph.D., whose telephone number is (571) 272-0908. The examiner can normally be reached Monday through Thursday from 10:30 AM to 9:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Bruce R. Campell, Ph.D., can be reached

Serial No.: 10/811,725 Applicant: Apte, S.

at (571) 272-0974. Direct general status inquiries to the Technology Center 1600 receptionist at (571) 272-1600. Informal communications may be submitted to the Examiner's RightFAX account at (571) 273-0908.

Applicants are reminded that the United States Patent and Trademark Office (Office) requires most patent correspondence to be: a) faxed to the Central FAX number (571-273-8300) (updated as of July 15, 2005), b) hand carried or delivered to the Customer Service Window (now located at the Randolph Building, 401 Dulany Street, Alexandria, VA 22314), c) mailed to the mailing address set forth in 37 C.F.R. § 1.1 (e.g., P.O. Box 1450, Alexandria, VA 22313-1450), or d) transmitted to the Office using the Office's Electronic Filing System. This notice replaces all prior Office notices specifying a specific fax number or hand carry address for certain patent related correspondence. further information refer to the Updated Notice of Centralized Delivery and Facsimile Transmission Policy for Patent Related Correspondence, and Exceptions Thereto, 1292 Off. Gaz. Pat. Office 186 (March 29, 2005).

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Respectfully,

Jeffrey S. Parkin, Ph.D.

Trimary Examiner
Art Unit 1648

07 January, 2007